Literature DB >> 11932266

The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study.

Pekka Kunelius1, Olavi Lukkarinen, Minna L Hannuksela, Outi Itkonen, Juha S Tapanainen.   

Abstract

The objective of the study was to investigate the effects of dihydrotestosterone (DHT) gel on general well-being, sexual function, and the prostate in aging men. A total of 120 men participated in this randomized, placebo-controlled study (60 DHT and 60 placebo). All subjects had nocturnal penile tumescence once per week or less, andropause symptoms, and a serum T level of 15 nmol/liter or less and/or a serum SHBG level greater than 30 nmol/liter. The mean age was 58 yr (range, 50-70 yr). Of these subjects, 114 men completed the study. DHT was administered transdermally for 6 months, and the dose varied from 125-250 mg/d. General well-being symptoms and sexual function were evaluated using a questionnaire, and prostate symptoms were evaluated using the International Prostate Symptoms Score, transrectal ultrasonography, and assay of serum prostate-specific antigen. Early morning erections improved transiently in the DHT group at 3 months of treatment (P < 0.003), and the ability to maintain erection improved in the DHT group compared with the placebo group (P < 0.04). No significant changes were observed in general well-being between the placebo and the DHT group. Serum concentrations of LH, FSH, E2, T, and SHBG decreased significantly during DHT treatment. Treatment with DHT did not affect liver function or the lipid profile. Hemoglobin concentrations increased from 146.0 +/- 8.2 to 154.8 +/- 11.4 g/liter, and hematocrit from 43.5 +/- 2.5% to 45.8 +/- 3.4% (P < 0.001). Prostate weight and prostate-specific antigen levels did not change during the treatment. No major adverse events were observed. Transdermal administration of DHT improves sexual function and may be a useful alternative for androgen replacement. As estrogens are thought to play a role in the pathogenesis of prostate hyperplasia, DHT may be beneficial, compared with aromatizing androgens, in the treatment of aging men.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932266     DOI: 10.1210/jcem.87.4.8138

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 3.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

Review 4.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

5.  Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Authors:  Shalender Bhasin; Thomas G Travison; Thomas W Storer; Kishore Lakshman; Manas Kaushik; Norman A Mazer; Ahn-Hoa Ngyuen; Maithili N Davda; Hernan Jara; Adam Aakil; Stephan Anderson; Philip E Knapp; Samson Hanka; Nurahmed Mohammed; Pierre Daou; Renee Miciek; Jagadish Ulloor; Anqi Zhang; Brad Brooks; Katie Orwoll; Leife Hede-Brierley; Richard Eder; Ayan Elmi; Geeta Bhasin; Lauren Collins; Ravinder Singh; Shehzad Basaria
Journal:  JAMA       Date:  2012-03-07       Impact factor: 56.272

6.  Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.

Authors:  Stephanie T Page; Daniel W Lin; Elahe A Mostaghel; Brett T Marck; Jonathan L Wright; Jennifer Wu; John K Amory; Peter S Nelson; Alvin M Matsumoto
Journal:  J Clin Endocrinol Metab       Date:  2010-12-22       Impact factor: 5.958

Review 7.  Erythrocytosis Following Testosterone Therapy.

Authors:  Samuel J Ohlander; Bibin Varghese; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2017-05-16

Review 8.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Treatment of Men for "Low Testosterone": A Systematic Review.

Authors:  Samantha Huo; Anthony R Scialli; Sean McGarvey; Elizabeth Hill; Buğra Tügertimur; Alycia Hogenmiller; Alessandra I Hirsch; Adriane Fugh-Berman
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

10.  Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.

Authors:  Phillip M Pierorazio; Luigi Ferrucci; Anna Kettermann; Dan L Longo; E Jeffrey Metter; H Ballentine Carter
Journal:  BJU Int       Date:  2009-09-14       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.